In a study of patients with ERA or other SpAs, the primary rationale cited by physicians for initiating TNF inhibitor therapy was the presence of active disease, as determined by physical examination (61%), exceeding the combined presence of both physical examination findings and abnormal imaging (14%) or abnormal imaging alone (24%) [47]. Here, TNF is linked to enthesitis-related juvenile idiopathic arthritis.